The regular use of various nonsteroidal anti-inflammatory drugs (NSAIDs) was shown to decrease the incidence of colorectal cancer. This effect is thought to be caused predominantly by inhibition of cyclooxygenase-2 (COX-2) and, subsequently, prostaglandin synthesis. However, recent studies have suggested that COX-independent pathways may contribute considerably to these antiproliferative effects. To evaluate the involvement of COX-dependent and COXindependent mechanisms further, we assessed the effects of celecoxib (selective COX-2 inhibitor) and SC560 (selective COX-1 inhibitor) on cell survival, cell cycle distribution, and apoptosis in three colon cancer cell lines, which differ in their expression of COX-2. Both drugs induced a G 0 /G 1 phase block and reduced cell survival independent of whether or not the cells expressed COX-2. Celecoxib was more potent than SC560. The G 0 /G 1 block caused by celecoxib could be attributed to a decreased expression of cyclin A, cyclin B1, and cyclin-dependent kinase-1 and an increased expression of the cell cycle inhibitory proteins p21
and its purity, which was >98%. SC560 (selective COX-1 inhibitor), synthesized by Witega (Berlin, Germany), had a purity of >99%. Both substances were dissolved in DMSO (dimethyl sulfoxide) and were diluted further in phosphate buffered saline (PBS) or culture medium.
Colony forming assay
We seeded cells in 5-cm-diameter dishes at a density of 500 cells/dish and incubated them for 16 h at 37°C in a 5% CO 2 atmosphere. Cells were then treated with celecoxib or SC560 at increasing concentrations of 0-50 µM and were incubated for another 10 days. At the end of the incubation period cells were fixed with 100% methanol and stained with 0.5% crystal violet, 5% Giemsa solution. We counted single cell clones by using the Quantity one software (BIO-RAD, München, Germany). The number of untreated control cell clones was referred to as 100% survival rate, and we calculated the percentage of survival rate after treatment in relation to untreated control cells. We calculated the IC 50 by using a standard sigmoidal Emax model.
Apoptosis ELISA
Induction of apoptosis was assessed by using a "Cell Death Detection ELISA" (Roche Diagnostics, Mannheim, Germany). This test is based on the detection of DNA-histone complexes in the form of mono-and oligo-nucleosomes, which are generated during apoptosis. Cells (1×10 5 ) were incubated for 16-20 h at 37°C in 5% CO 2 in 5-cm dishes and then were treated for 6 h with various concentrations (10, 50 , and 100 µM) of celecoxib or SC560, respectively. Cells were harvested by trypsinization and washed two times with PBS. 10 4 cells were used for the ELISA. We performed the test according to the manufacturer protocol.
Detection of cell cycle distribution and apoptosis by flow cytometry
HCT-15, Caco-2, and HT-29 cells (5×10 5 ) were incubated for 48 h in medium without FCS at 37°C in 5% CO 2 for synchronization of the cell cycle. Cells were then treated for 24 h with either 0.1% DMSO (controls) or various concentrations (25, 50, 75 , or 100 µM) of celecoxib or SC560, respectively. We added treatments in medium containing 10% FCS. Cells were harvested by trypsinization, washed two times with PBS, fixed with ethanol, incubated for 5 min with 0.125% Triton X-100, and stained with propidium iodide in PBS containing 0.2 mg/ml RNAse A. Stained cells were analyzed by flow cytometry (Beckton Dickinson, Heidelberg, Germany). For each sample, cells were counted until 10,000 cells had been counted in a predefined G 1 -gate. The cell cycle distribution, that is, the percentage of cells in the G 0 /G 1 , S, and G 2 /M phase, was assessed by using the WinMDI 2.8 software (http://facs.scripps.edu/software.html). The percentage of apoptotic cells was assessed by calculating the percentage of cells in the sub-G 1 phase (20) .
Western blot analysis
Cells (5×10 5 ) were seeded per 5-cm dish. After 16 h, cells were incubated for 6 h with various concentrations (10, 50, or 100 µM) of celecoxib or SC560, respectively, or cells were incubated with 100 µM celecoxib or SC560 for various times (0, 0.5, 2, 4, 6, 8, 16, or 24 h). After we washed the cells with PBS, they were harvested by scraping them into 1 ml PBS followed by short centrifugation. Cell pellets were resuspended in 1 ml lysis-buffer (20 mM Tris-HCl [pH 8.5]), 1 mM EDTA [ethylenediaminetetraacetate], 1 mM PMSF [phenylmethylsulfonyl fluoride]), sonicated, and centrifuged. We determined the amount of protein of the supernatants by using the Bradford method. Aliquots of 50 µg of total protein extract were separated electrophoretically by 10% or 12% sodium dodecylsulfate polyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane (Amersham Life Science, Freiburg, Germany). Equal loading of the gel was checked by ponceau staining (3% trichloroacetic acid, 0.1% ponceau). After overnight incubation of the membrane in blocking buffer (5% nonfat dry milk, 0.3% Tween 20 in PBS), it was incubated for 2 h with the respective primary antibody directed against COX-1 (1:100), COX-2 (1:100), poly (ADP) ribose polymerase (PARP) (1:100), cyclin-dependent kinase (Cdk)-1 (1:100), cyclin A (1:100), cyclin B1 (1:100), p21 Waf1 (1:100), p27 Kip1 (1:100), or Erk-2 (1:1000) (all antibodies were purchased from Santa Cruz Biotechnology, Heidelberg, Germany) diluted in blocking buffer at room temperature, washed three times with 0.3% Tween 20/PBS for 10 min, and then incubated with a peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology) in blocking buffer. After being rinsed extensively in 0.3% Tween 20/PBS, protein-antibody complexes were visualized by using ECL (Amersham Pharmacia Biotech, Freiburg, Germany) according to the manufacturer protocol.
Tumor proliferation in nude mice
We used 7-week-old NMRI-nu/nu mice (Harlan Winkelmann GmbH, Borchen, Germany). HCT-15 or HT-29 cells (suspended in PBS) were injected subcutaneously at the right and left dorsal flank (1×10 7 cells per mouse). Mice were treated for 3 weeks with 10, 25, or 100 mg/kg/day celecoxib (suspended in PBS) or 10 or 100 mg/kg/day SC560 (suspended in 1% Tylose, 1% soybean lecithin in water) or they were left untreated. The first dose was administered directly after tumor cell injection. Because effects of celecoxib on HCT-15 tumors were similar at 10 and 100 mg/kg, only one dose of 25 mg/kg was used for HT-29 induced tumors. Celecoxib and SC560 were administered orally with a gastric tube. In each group, five to six mice were treated. The tumor volume was assessed every 2-3 days with the calliper rule. After administration of the last dose (2-4 h), mice were killed and blood was sampled for determination of celecoxib and SC560 plasma concentrations. The animal experiments were approved by the local Ethics Committee for Animal Research.
Determination of celecoxib and SC560 plasma concentrations
Mouse plasma samples were extracted by solid-phase extraction as has been described previously (21) , and the eluate was analyzed for celecoxib or SC560, respectively. Calibration standards were prepared in drug-free plasma. To control for inter-assay variation, we measured spiked quality control samples in plasma in each run in randomized order among samples. Celecoxib was analyzed by using liquid chromatography coupled with tandem massspectrometry as has been described previously (22) . SC560 was analyzed by high performance liquid chromatography (HPLC). The HPLC unit consisted of a Gastorr 153 degasser, a Jasco LG-980-02S ternary gradient unit, a Jasco PU-1580 pump, a Jasco AS 951 autosampler, and a Jasco FP-920 fluorescence detector (Jasco, GrossUmstadt, Germany). The detector was set at an excitation wavelength of 228 nm and an emission wavelength of 420 nm. The column used was a Phenomenex Luna Phenyl-Hexyl column (100 × 2 mm, 3-µm particle size, and 100 Å pore size). The mobile phase consisted of water/acetonitrile/formic acid (48.5:51.5:0.1 v/v/v). The flow rate was set at 0.4 ml/min. A volume of 80 µl of the extracted sample was injected onto the column. The analytical data output was processed by Jasco Borwin software (version 1.50). The coefficient of correlation for all measured sequences was at least 0.99. The intra-day and inter-day variability was <5%, and the lower limit of quantification was 0.25 ng/ml.
Statistics
Data are presented as mean ± SE. SPSS 9.01 was used for statistical analyses. For comparison of survival data, the number of visible cell clones following celecoxib, SC560, or vehicle treatment were submitted to univariate analysis of variance (ANOVA) and subsequent t-tests vs. control using a Dunnett correction for multiple comparisons. Separate ANOVAs were performed for each drug and cell line. Data of the apoptosis ELISA were also submitted to univariate ANOVA and subsequent t-tests by using a Bonferroni α-correction for multiple comparisons. To compare the tumor growth in nude mice, the area under the tumor volume vs. time curves were calculated by using the linear trapezoidal rule. AUCs (area under the curves) were submitted to univariate ANOVA. Treatments were then compared mutually by using t-tests with a Bonferroni α-correction for multiple comparisons. For all statistical tests, α was set at 0.05.
RESULTS

Cyclooxygenase expression
As a prerequisite for our experiments, the varying expression of COX-2 among the cell lines was confirmed by Western blot analysis with untreated HCT-15, Caco-2, and HT-29 cells. As shown in Figure 1A , all three cell lines expressed COX-1 protein constitutively. As expected, COX-2 protein was not expressed in HCT-15 cells but in Caco-2 and HT-29 cells ( Figure 1B ).
Cell survival
To evaluate whether the expression of COX-2 determined the sensitivity toward the selective COX-2 inhibitor celecoxib or the selective COX-1 inhibitor SC560, we assessed the cell survival in the colony-forming assay (Fig. 2) . HT-29 were the most sensitive cells toward celecoxib treatment (IC 50 =11.4 µM; coefficient of variation CV=19.0%). The IC 50 of celecoxib was 22.2 µM (CV=8.1%) and 26.5 µM (CV=28.1%) for HCT-15 and Caco-2 cells, respectively. SC560 was most potent toward Caco-2 cells with an IC 50 of 12.4 µM (CV=8.7%). The IC 50 values for HCT-15 and HT-29 cells were 25.7 µM (CV=8.6%) and 18.6 µM (CV=8.6%), respectively. Thus, there was no obvious relationship between the observed cell survival and COX-2 protein expression. Statistical results are shown in Figure 2 .
Induction of apoptosis
To explore potential mechanisms for the observed cell killing we assessed whether the drugs induced apoptosis. DNA fragmentation was assessed by measuring mono-and oligonucleosomes by using a commercially available enzyme immunoassay kit (Fig. 3) . Celecoxib (100 µM for 6 h) induced DNA cleavage in all three cell lines, whereby HT-29 was the most sensitive cell line. Conversely, SC560 did not significantly induce DNA cleavage in any of the cell lines used. Statistical results are shown in Figure 3 .
We assessed PARP cleavage as a second marker for apoptosis by using Western blot analysis. PARP is a 112-kDa nuclear protein that is cleaved specifically by activated caspase-3 and -6 into a 85-kDa and a 29-kDa apoptotic fragment. With celecoxib (100 µM), PARP cleavage was observed in all three cell lines. SC560 (up to 100 µM) had no effect (Fig. 4) .
In addition, we used flow cytometry to determine the percentage of cells in the subG 1 phase, which is the apoptotic fraction. As shown in Figure 5 A-C and Table 1 , treatment of cells with celecoxib (100 µM) clearly increased the subG 1 -fraction in HCT-15 and Caco-2 cells and, to a minor degree, also in HT-29 cells. In contrast, 100 µM SC560 caused only a slight increase of the subG 1 -fraction in each cell line (Table 1) . Thus, celecoxib clearly induced apoptotic cell death in colon cancer cells irrespective of the COX-2 expression.
Cell cycle distribution and expression of cyclin-dependent kinase -1, cyclin A, and cyclin B1, as well as cell cycle inhibitory proteins p21
Waf1 and p27
Kip1
Because apoptosis often occurs as a consequence of a cell cycle block, we were interested in whether the observed cytotoxicity of celecoxib and SC560 was mediated through an alteration of the cell cycle. As determined by flow cytometry, treatment with celecoxib and SC560 caused a concentration-dependent inhibition of the progression from the G 0 /G 1 to S and G 2 /M phase in all three cell lines, which resulted in a clear increase of the percentage of cells in the G 0 /G 1 phase compared with control cells. In each cell line celecoxib was more potent than SC560 (Fig. 5 A-C and Table 1 ). Thus, celecoxib caused a G 0 /G 1 -cell cycle block independent of whether the cells expressed COX-2 or not. Supplementation with increasing concentrations of PGE 2 (0.1-10 µg/ml) did not prevent the G 0 /G 1 block (data not shown).
The progression through the various phases of the cell cycle is promoted by cyclins and Cdks and inhibited by Cdk inhibitors such as p21
Waf1 and p27 Kip1 (23) (24) (25) (26) . Cdks participating in the regulation of the cell cycle progression include: i) Cdk-4 (27) and Cdk-6 (28), which control the progression through G 1 together with D-type cyclins; ii) Cdk-2, which regulates the G 1 /S transition in association with cyclin E (29-32); and iii) Cdk-1, which, in concert with type-A and -B cyclins, controls the G 2 /M phase transition (33) (34) (35) (36) . The cell cycle inhibitory proteins p21
Waf1 and p27 Kip1 block cell cycle progression at both the G 1 /S and the G 2 /M cell cycle transition. In general, the expression of Cdks does not change appreciably throughout the cell cycle. Thus, the Cdk activity is regulated mostly by the expression pattern of the different cyclins and Cdk inhibitors.
Because celecoxib and, to a lesser extent, SC560 inhibited the transition through the cell cycle and led to an accumulation of cells in the G 0 /G 1 phase, we hypothesized that the underlying molecular mechanisms might involve changes in the expression or activity of cell cycle regulatory proteins. To test this hypothesis we assessed the protein expression of Cdk-1, cyclin A, cyclin B1, p21
Waf1 , and p27 Kip1 by means of Western blot analysis (Fig. 6A-C and Fig. 7A,  B) . In all three cell lines, a marked time-dependent decrease of cyclin A and B expression was observed when cells were treated with 100 µM celecoxib. Cdk-1 protein levels also decreased, although to a lesser extent than those of both cyclins. Conversely, the expression of p21
Kip1 increased in a time-dependent manner. The effect of celecoxib was first observed at 4 h and was maximal at 24 h. Thus, the time-dependent expressional changes of the cyclins, Cdk-1, and the Cdk inhibitors corresponded with the effects on cell cycle progression. In contrast to celecoxib, SC560, which also induced a slight G 0 /G 1 phase block, did not affect the expression of the cell cycle regulatory proteins tested (data not shown).
Tumor growth in nude mice
To assess the relevance of the in vitro data, we implanted HCT-15 and HT-29 cells subcutaneously into nude mice. Mice were treated daily with celecoxib (10, 25, or 100 mg/kg/day) or SC560 (10 or 100 mg/kg/day) for three weeks. Proliferation of HCT-15 (COX-2 deficient) colon cancer xenografts treated with 10 or 100 mg/kg/day celecoxib was reduced significantly at each dose tested (F(2;15)=9.76, P=0.02; post hoc: P=0.01, and P=0.004 for 10 and 100 mg/kg/day, respectively) ( Fig. 8A ). SC560 (10 or 100 mg/kg/day) also reduced HCT-15 tumor growth (F(2;12)=7.37, P=0.008; post hoc: P=0.05, and P=0.008 for 10 and 100 mg/kg/day, respectively) ( Fig. 8C) . In contrast, HT-29 tumor growth was neither influenced by celecoxib (25 mg/kg/day) (F(1;7)=1.51, P=0.258) nor by SC560 (F(2;12)=1.03, P=0.384) (Fig.  8B and D) . Plasma concentrations between 2 and 4 h after administration of the last celecoxib dose were 0.77 ± 0.05 µM (10 mg/kg), 1.4 ± 0.25 µM (25 mg/kg), and 3.8 ± 0.72 µM (100 mg/kg). Plasma concentrations of SC560 were 0.8 ± 0.12 µM (10 mg/kg) and 1.6 ± 0.52 µM (100 mg/kg).
DISCUSSION
We show in the present study that both the selective COX-2 inhibitor celecoxib and, to a lesser extent, the selective COX-1 inhibitor SC560 inhibit the transition from the G 0 /G 1 to the S phase of the cell cycle in colon cancer cells in a concentration-dependent manner. In case of celecoxib, this effect was associated with a decrease of the expression of cyclins and an increase of the expression of the cell cycle inhibitory proteins p21
Waf1 and p27 Kip1 . Moreover, celecoxib induced apoptosis in these cells. The effects were independent of the COX-2 status of the cells. These results strongly suggest that the antitumor activity of celecoxib is independent of its COX-2 inhibitory properties. This theory is supported further by a comparison of the concentrations of celecoxib and SC560 needed to inhibit COX-activity and those needed to achieve antiproliferative effects. The IC 50 of celecoxib for COX-1 and COX-2 inhibition (measured in the human whole blood assay) was reported to be 6.7 ± 0.9 µM and 0.87 ± 0.18 µM, respectively (37) . Concentrations required to inhibit tumor cell proliferation in the present and in a previous study (38) were in the range of 50 µ to 100 µM. For SC560, COX-1 inhibitory concentrations (0.01 µM) (39) were also about 4 orders of magnitude lower than those needed to induce a cell cycle arrest. It may be argued that the in vitro effects, which occurred only at such high concentrations, are not of clinical relevance because these concentrations normally are not reached in vivo. However, recently it has been shown that celecoxib reduced polyp growth in patients with familial adenomatous polyposis (4) at doses of 800 mg/day. The recommended anti-inflammatory dose of celecoxib (100-200 mg b.i.d.) had no significant effect in this particular study, again suggesting that high celecoxib concentrations are required for the protective effects. The plasma concentrations of celecoxib in our nude mice experiments (3-4 µM at 100 mg/kg) were in the range of those found in human plasma following administration of a single 800 mg dose (3-5 µM) (22) .
Antitumor effects with other NSAIDs, such as sodium salicylate or sulindac and its metabolite sulindac sulfide, were also observed at rather high concentrations only (5-20 mM for sodium salicylate, 1200 µM for sulindac, and 200 µM for sulindac sulfide). These drugs also induced a G 0 /G 1 cell cycle block and caused alterations of the expression of cell cycle regulatory proteins (40) (41) (42) . This finding suggests that the mechanisms involved in the antiproliferative effects of these drugs are similar to those found for celecoxib in the present study.
The celecoxib-induced alterations of cell cycle regulatory proteins might have been mediated through an activation of stress related transcription factors such as p53, AP-1, or NF-κB, which are known to be involved in the transcriptional regulation of these genes (43) (44) (45) (46) . This suggestion is supported by our recent finding that the transcription factor NF-κB is activated in the presence of high celecoxib concentrations (22) . The observed NF-κB activation was associated with an increase of NF-κB dependent gene transcription and a loss of the antiinflammatory activity. Although this might affect the therapeutic effect of celecoxib in inflammatory disorders negatively, it might be favorable for colon cancer prevention because it has been shown that activation of NF-κB in colon cancer cells is associated with an increase of apoptosis in these cells (46) . This hypothesis is supported by a recent study that revealed that high concentrations of aspirin (5-10 mM) might induce apoptotic cell death in colon cancer cells by activation of NF-κB (47).
Besides its effects on NF-κB and cell cycle regulatory proteins, celecoxib was reported to inhibit the activation of protein kinase B (PKB)/Akt in prostate cancer cells (38) . This effect was associated with induction of apoptosis, suggesting that inhibition of PKB/Akt also contributes to the antiproliferative activity of celecoxib in certain carcinomas.
In contrast to celecoxib, SC560 had no effect on the expression of the cell cycle regulatory proteins tested; although it also induced a slight G 0 /G 1 -cell cycle block. Additionally, SC560 did not induce apoptosis. However, in vivo effects of SC560 partly resembled those of celecoxib; that is, it also reduced the proliferation of HCT-15 xenografts in nude mice. The mechanisms underlying the antiproliferative effects of SC560 are not clear, but they are probably caused by different effects than those of celecoxib. Because SC560 is a potent COX-1 inhibitor, it is conceivable that its antiproliferative effects in vivo are mediated through inhibition of the COX-1 activity of endothelial cells, which might affect angiogenesis and thereby tumor growth (48) .
In summary, we have shown in the present study that celecoxib as well as SC560 have an antiproliferative effect on human colon carcinoma cell lines in vitro and in vivo. The effects of celecoxib are mediated at least in part through the induction of a cell cycle block and apoptosis and are independent of the COX-2 expression of the cells. were treated with celecoxib (A) or SC560 (B), or they were left untreated and incubated until distinct single clones were visible. Cells were fixed with MeOH and stained with 0.5% crystal violet, 5% Giemsa solution. Single-cell clones were counted. The mean number of untreated control cell clones was set at 100%. Data are mean ± SE of three independent experiments. ANOVA plus subsequent Dunnett post hoc tests were used for statistical comparisons. *Statistically significant result with P < 0.05. Table 1 ). For western blot analysis, 50 µg of total protein extract was separated on a 12% SDS-polyacrylamide gel and electro blotted onto a nitrocellulose membrane which was incubated with specific antibodies directed against p21
Kip1 or p27 Waf1 . Statistical comparisons of the areas under the "tumor volume" vs. "time curves" revealed that both celecoxib and SC560 significantly reduced the growth of HCT-15 tumors (P<0.05) at the doses tested but had no effect on HT-29 tumors.
